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Autism spectrum disorders (ASD) are complex neu-
rodevelopmental diseases in which different combi-
nations of genetic mutations may contribute to the
phenotype. Using Rett syndrome (RTT) as an ASD
genetic model, we developed a culture system using
induced pluripotent stem cells (iPSCs) from RTT
patients’ fibroblasts. RTT patients’ iPSCs are able
to undergo X-inactivation and generate functional
neurons. Neurons derived fromRTT-iPSCs had fewer
synapses, reduced spine density, smaller soma size,
altered calcium signaling and electrophysiological
defects when compared to controls. Our data uncov-
ered early alterations in developing human RTT
neurons. Finally, we used RTT neurons to test the
effects of drugs in rescuing synaptic defects. Our
data provide evidence of an unexplored develop-
mental window, before disease onset, in RTT
syndrome where potential therapies could be
successfully employed. Our model recapitulates
early stages of a human neurodevelopmental
disease and represents a promising cellular tool for
drug screening, diagnosis and personalized treat-
ment.INTRODUCTION
Autism spectrum disorders (ASD) are complex neurodevelop-
mental diseases affecting 1 in 150 children in the United States
(Autism and Developmental Disabilities Monitoring Network
Surveillance Year 2000 Prinicipal Investigators; Centers for
Disease Control and Prevention, 2007). Such diseases are
mainly characterized by impaired social interaction and repeti-
tive behavior. Family history and twin studies suggest that, insome cases, these disorders share genetic roots, but the degree
to which environmental and genetic patterns account for indi-
vidual differences within ASD is currently unknown (Piven
et al., 1997; Ronald et al., 2006). A different combination of
genetic mutations is likely to play a role in each individual. Never-
theless, the study of mutations in specific genes can help to
identify molecular mechanisms responsible for subtle alterations
in the nervous system, perhaps pointing to common mecha-
nisms for ASD.
Rett syndrome (RTT) is a progressive neurological disorder
caused by mutations in the X-linked gene encoding MeCP2
protein (Amir et al., 1999). RTT patients have a large spectrum
of autistic characteristics and are considered part of the ASD
population (Hammer et al., 2002; Samaco et al., 2005, 2004;
Zappella et al., 2003). These individuals undergo apparently
normal development until 6–18 months of age, followed by
impaired motor function, stagnation and then regression of
developmental skills, hypotonia, seizures and autistic behavior
(Amir et al., 1999). MeCP2 may be involved in the epigenetic
regulation of target genes, by binding to methylated CpG dinu-
cleotides within promoters, andmay function as a transcriptional
repressor, although this view has been challenged recently
(Chahrour et al., 2008; Yasui et al., 2007).
Pluripotent human embryonic stem cells (hESCs) have been
successfully generated from early stage human embryos and
can differentiate into various cell types (Thomson et al., 1998).
However, to develop cellular models of human disease, it is
necessary to generate cell lines with genomes predisposed to
diseases. Recently, reprogramming of somatic cells to a pluripo-
tent state by overexpression of specific genes (induced pluripo-
tent stem cells, iPSCs) has been accomplished (Takahashi and
Yamanaka, 2006; Yu et al., 2007). Isogenic pluripotent cells are
attractive not only for their potential therapeutic use with lower
risk of immune rejection but also for understanding complex
diseases (Marchetto et al., 2010; Muotri, 2008). Although iPSCs
have been generated for several neurological diseases (Dimos
et al., 2008; Ebert et al., 2009; Hotta et al., 2009; Lee et al.,
2009; Park et al., 2008; Soldner et al., 2009), the demonstrationCell 143, 527–539, November 12, 2010 ª2010 Elsevier Inc. 527
of disease-specific pathogenesis and phenotypic rescue in rele-
vant cell types is a current challenge in the field (Marchetto et al.,
2010).
We have developed a human model of RTT by generating
iPSCs from fibroblasts of RTT patients carrying different
MeCP2 mutations and unaffected individuals. We show that
RTT-iPSCs retained the capacity to generate proliferating neural
progenitor cells (NPCs) and functional neurons that underwent
X-inactivation. We observed a reduced number of dendritic
spines and synapses in iPSC-derived neurons. Moreover, we
detected an altered frequency of intracellular calcium spikes
and electrophysiological defects in RTT-derived neuronal
networks, revealing potential new biomarkers for RTT pathology.
Gain and loss of function experiments in iPSC-derived neurons
confirmed that some of the alterations observed were related
to MeCP2 expression levels. Finally, we used the iPSC system
to test candidate drugs to rescue synaptic deficiency in RTT
neurons. Together, our results suggest that RTT and other
complex CNS diseases can be modeled using the iPSC tech-
nology to investigate the cellular and molecular mechanisms
underlying their abnormalities.RESULTS
Generation of iPSCs from RTT Patients and Normal
Individuals
Nonaffected control fibroblasts and cells carrying four distinct
MeCP2 mutations (Figure 1A and Table S1 available online) iso-
lated from clinically affected female patients with RTT symptoms
were infected with retroviral reprogramming vectors (Sox2,
Oct4, c-Myc and Klf4), as described elsewhere (Takahashi
et al., 2007). After 2 to 3weeks, compact iPSC colonies emerged
from a background of fibroblasts (Figures 1B and 1C). Colonies
were manually picked and transferred to matrigel (Figures 1D
and 1E). We obtained at least 10 clones from each control
(WT)-iPSC and RTT-iPSC that continuously expressed pluripo-
tent markers such as Nanog, Lin28, Tra-1-81 and Sox2 (Figures
1F and 1G and Figures S1A–S1C). All iPSC clones used in this
study maintained a normal karyotype (Figure 1H). Teratomas
containing derivatives from all 3 embryonic germ layers
confirmed that the iPSCs were able to differentiate in vivo (Fig-
ure 1I). PCR fingerprinting confirmed their derivation from
respective fibroblasts (data not shown). Next, we asked if the
global molecular signatures of RTT-iPSC clones carrying the
two distinct MeCP2 mutations (1155del32 and Q244X) and
WT-iPSC clones (from AG09319) resembled those of available
hESC lines (HUES6). Gene expression profiles measured using
human genome Affymetrix Gene Chip arrays were grouped by
hierarchical clustering, and correlation coefficients were
computed for all pair-wise comparisons (GEO accession number
GSE21037). We observed that the WT-iPSC and RTT-iPSC
clones were almost indistinguishable. The results clearly re-
vealed that the iPSC and hESC lines were more similar to each
other than to the respective original fibroblasts (Figure S1D).
These findings, combined with manual inspection of the gene
expression of known pluripotent- and fibroblast-related genes
(Figures S1E and S1F), indicated that the reprogramming was528 Cell 143, 527–539, November 12, 2010 ª2010 Elsevier Inc.successful. In Table S2 we present a summary of all iPSC
subjects and clones utilized for each experiment.
Neural Induction of iPSCs
Our protocol for neuronal differentiation is outlined in Figure 2A.
We initiated neural differentiation by plating embryoid bodies
(EBs). After a week, EB-derived rosettes became apparent (Fig-
ure 2B). Rosettes were then manually collected, dissociated and
re-plated. The NPCs derived from rosettes formed a homoge-
neous population after a couple of passages. NPCs were
positive for early neural precursor markers, such as Nestin,
Sox1-2 and Musashi1 (Figure 2C). To obtain mature neurons,
EBs in the presence of retinoic acid (RA) were dissociated and
re-plated (Figure 2B). At this stage, cells were positive for Tuj1
(b-III-Tubulin) and Map2 (Microtubule-associated protein 2) (Fig-
ure 2D). Moreover, we detected expression of GABA (g-amino
butyric acid) and VGLUT1 (vesicular glutamate transpoter-1).
We also observed synapsin puncta outlining Map2-positive neu-
rites (Figure 2D). We did not detect a significant alteration in RTT
neuronal survival when compared to controls, as measured by
Map2 staining (Figure 2E and Figure S2A). In addition, infection
with a lentivirus expressing the DsRed gene under the control
of Synapsin promoter (Syn::DsRed) did not reveal any difference
in neuronal survival between RTT and controls (Figure 2E and
Figure S2B). Interestingly, the number of GABA-positive neurons
was also not affected between RTT and controls (Figure 2F and
Figure S2C).
X-Inactivation during Neuronal Differentiation
of RTT-iPSCs
In female hESCs, both chromosomes should be active, but one X
chromosome becomes silenced upon differentiation (Dhara and
Benvenisty, 2004). Similar to ESCs, female mouse iPSCs have
shown reactivation of a somatically silenced X chromosome
and have undergone random X-inactivation upon differentiation
(Maherali et al., 2007). Because MeCP2 is an X-linked gene,
we examined the ability of our RTT-iPSCs clones to reset the X
chromosome (i.e., to erase X-inactivation) and whether X-inacti-
vation would take place again after neuronal differentiation (Fig-
ure 3A). We stained RTT-iPSCs clones and their respective fibro-
blasts with an antibody against trimethylated histone 3 Lysine 27
(me3H3K27), an epigenetic silencingmarker present on the inac-
tive X chromosome in interphase nuclei (Silva et al., 2003). Some,
but not all, undifferentiated RTT-iPSCs clones displayed diffuse
immunoreactivity throughout the nucleus, similar to some
hESCs, showing that the memory of the previous inactivation
state had been erased (Figure 3B). For further analysis, we only
selected clones that displayed a diffuse me3H3K27 pattern to
differentiate into neurons. Upon neuronal differentiation, intense
nuclear foci staining, a prominent diagnostic of the inactive X,
was found in 80% of neurons labeled by the infection of a lenti-
virus carrying the neuron-specific Synapsin promoter driving the
EGFP reporter (Syn::EGFP). Nuclear foci were also present in
RTT fibroblasts before reprogramming (Figure 3B). We quanti-
fied the percentage of cells displaying either a diffuse or intense
X-inactivation (nuclear foci) (Figure 3C). Our data suggest that
the majority of cells in selected clones from both hESCs (99%)
and iPSCs (95%) have a diffuse pattern. In contrast,
Figure 1. Generation of iPSCs
(A) Schematic representation of the MeCP2 gene
structure and mutations used in this study. UTR,
untranslated region; MBD, methyl-CpG binding
domain; NLS, nuclear localization signal; Poly-A,
polyadenylation signal; TRD, transcriptional
repression domain; WW, domain-containing
WW; X, stop codon. Respective cell-line codes
are shown close to their mutations.
(B) Morphology of human fibroblasts before retro-
viral infection.
(C) Aspect of iPSCs colonies 14 days after infec-
tion.
(D and E) Representative images of established
iPSC colonies.
(F and G) Representative images of RTT-iPSCs
showing expression of pluripotent markers.
(H) No karyotypic abnormalities were observed.
(I) Representative images of teratoma sections.
The scale bar represents 100 mm.
See also Figure S1.differentiated populations of fibroblasts and iPSC-derived
neurons have me3H3K27 nuclear foci staining, indicating
X-inactivation.
We also used fluorescent in situ hybridization (FISH) to visu-
alize Xist RNA, a noncoding transcript involved in X chromo-
some silencing that physically wraps the inactive X (Lucchesi
et al., 2005). Before reprogramming, the majority of fibroblasts
exhibit a clear Xist cloud. The signal is lost after reprogramming,
indicating that selected iPSC clones have two active X chromo-
somes in our culture conditions. A Xist cloud is also observed in
iPSC-derived neurons (Figure 3D). Fluorescent in situ hybridiza-
tion (FISH) analysis using a centromeric X chromosome probe in
iPSC-derived NPCs and neurons showed the presence of two XCell 143, 527–539, Nchromosomes (Figure 3E). As a con-
sequence of both X-chromosomes’
activation after reprogramming, the
MeCP2 protein can be detected in undif-
ferentiated iPSCs from RTT patients (Fig-
ure 3F). However, after differentiation,
RTT-iPSC-derived neurons recapitulated
X-inactivation and the population be-
came mosaic regarding MeCP2 expres-
sion. Immunostaining was performed
on several RTT-iPSC clones, and a
representative example of MeCP2
expression after differentiation is shown
in Figure 3F. Clones obtained from RTT
fibroblasts carrying the 1155del32
MeCP2 mutation do not produce a full-
length MeCP2 protein (Traynor et al.,
2002). Next, we selected one WT-iPSC
clone (WT-33 C1) and one RTT-iPSC
clone (1155del32 C15) to determine
whether the RTT-iPSC-derived neuronal
population showed reduced MeCP2
protein levels. As expected, we ob-
served a reduction in the full-lengthMeCP2 protein amounts in both fibroblasts and neurons
derived from the RTT-iPSC clone (Figure 3G). We tested the
original fibroblasts and iPSC-derived neurons from this patient
for X-inactivation using standard methodology for the androgen
receptor locus (Allen et al., 1992). RTT fibroblasts carrying
the 1155del32 MeCP2 mutation had a 55:45 distribution, but
RTT-derived neurons showed highly skewed X-inactivation,
with a 96:4 distribution (Figure S3). The outcome of the X-inac-
tivation process, measured by the androgen receptor locus,
seems to be consistent within the same clone. An independent
differentiation of the same clone (RTT-1155del32 C15) yielded
a 98:2 distribution. Unfortunately, androgen receptor locus
analysis was not conclusive for the MeCP2 mutation Q244Xovember 12, 2010 ª2010 Elsevier Inc. 529
Figure 2. Neural Differentiation of iPSCs
(A) Schematic view of the neural differentiation protocol.
(B) Representative images depicting morphological
changes during neuronal differentiation. The scale bar
represents 100 mm.
(C) NPCs are positive for neural precursor markers: Sox1,
Sox2, Musashi1, and Nestin. The scale bar represents
50 mm.
(D–F) (D) Representative images of cells after neuronal
differentiation. iPSC-derived neurons express mature
neuronal markers: GABA, Map2 and Synapsin. The scale
bar represents 20 mm. Similar numbers of Map2-positive
and Syn::DsRed-positive (E) as well as GABA-positive (F)
neurons from WT and RTT cultures.
Data shown as mean ± SEM. See also Figure S2.cells. However, a reduction of 50% in the amount of MeCP2
protein level (Figure S4E) is consistent with a random X-inacti-
vation. We have not analyzed the distribution for RTT-R306C
clones.530 Cell 143, 527–539, November 12, 2010 ª2010 Elsevier Inc.Our data show that X-inactivation was erased
in selected reprogrammed RTT-iPSCs clones
and subsequently restored during neuronal
differentiation. Importantly, the recapitulation
of X-inactivation produces mosaic neuronal
cultures with different ratios of cells expressing
normal MeCP2 levels, mimicking what is
observed in RTT patients’ brains. Our data do
not preclude that partial reprogramming from
a single fibroblast or retention of the X-inactiva-
tion would lead to clones with highly skewed
X-inactivation, where neurons would express
only the normal or mutant form of MePC2. In
fact, we do observe WT and RTT-iPSC clones
retaining X-inactivation after reprogramming.
The RTT-T158M C3-derived neurons showed
100:0 distribution. The expression of the mutant
MeCP2 allele was confirmed by sequencing.
Normal Cellular Proliferation
from RTT-iPSC-Derived NPCs
An increased incidence of large head size has
been reported in autism (Piven et al., 1995).
Other studies have suggested that the autistic
brain is smaller at birth, followed by rapid head
growth during early development and then
a period of reduced brain growth (Courchesne
et al., 2003). Head growth deceleration has
also been reported for RTT patients (Hagberg
et al., 2001). Since the cellular mechanism
behind this phenomenon is unknown, we inves-
tigated whether a perturbed NPC replication
cycle was affected in RTT. NPCs derived from
RTT-iPSCs, WT-iPSCs and hESCs (Cyth25
and HUES6) were generated and kept under
proliferating conditions in the presence of
FGF2. NPCs were derived using the same
protocol described above, had identicalpassage numbers and were analyzed for cell cycle by flow cy-
tometry. Our results showed no significant differences in any
cycle phase between HESC-, WT-iPSC- and RTT-iPSC-derived
NPCs (Figure 4A), though we cannot exclude the possibility that
altered head growth in RTT patients is caused by eventual
abnormal NPC proliferation in another developmental stage.
We then investigated potential phenotypic changes in RTT
neurons compared to controls.
Reduced Glutamatergic Synapse Number
and Morphological Alterations in RTT Neurons
Strong evidence implicates synapse alteration in ASD, including
RTT (Zoghbi, 2003). Loss of MeCP2 and doubling of MeCP2
dosage in mice have opposite effects on excitatory synapse
numbers in individual neurons (Chao et al., 2007). These results
suggest that MeCP2 may be a rate-limiting factor in regulating
glutamatergic synapse formation and indicate that changes
in excitatory synaptic strength may underlie global network
alterations in RTT. Therefore, we determined whether excitatory
synapse numbers were reduced in human RTT neurons. After
8 weeks of differentiation, glutamatergic neurons were identified
using antibodies against VGLUT1 (Takamori et al., 2000), and
dendrites were labeled with Map2 (Figure 4B). To confirm the
specificity of glutamatergic neurons in our cultures, we showed
that VGLUT1 puncta were mostly adjacent to the postsynaptic
density-95 (Psd95) protein (Niethammer et al., 1996) (Fig-
ure S4A). We found a reduction in the density of VGLUT1 puncta
from RTT-iPSCs clones carrying 3 different MeCP2 mutations
compared to HUES6 and distinct WT-iPSCs-derived Map2-
positive neurons, suggesting a specific defect in glutamate
transport in RTT cultures (Figure 4B and Figure S4B). Since
neurons carrying different MeCP2 mutations showed reduced
VGLUT1 puncta in our cultures, we tested whether loss of
function of MeCP2 was directly related to the number of gluta-
matergic synapses in our neuronal cultures. We cloned an
shRNA against MeCP2 in a lentiviral vector that is able to knock-
down both isoforms of MeCP2 (Figure S4C). Neurons derived
from WT-iPSCs expressing the shMeCP2 showed a similar
reduction in VGLUT1 puncta when compared to control neurons
expressing a scramble shRNA (shControl) (Figure 4C and Fig-
ure S4B). Overexpression of MeCP2 using a lentiviral vector
(Figure S4C) increased the number of VGLUT1 puncta in WT
and RTT neurons (Figure 4D and Figure S4B). Our data strongly
suggest that MeCP2 is a rate-limiting factor in regulating gluta-
matergic synapse number in human neurons.
We also investigated whether RTT neurons displayed any
morphological alteration when compared to controls. To
visualize neuronal anatomy, we infected the cultures with the
Syn::EGFP lentivirus. Morphological analysis of RTT neurons re-
vealed that the number of spines in RTT neurites was reduced
when compared to WT neurons and after ectopic expression
of shMeCP2 (Figure 4E). Consistent with this observation, the
number of spines in dendrites of neurons from postmortem
RTT patients’ brains was previously reported to be lower than
that in normal individuals (Chapleau et al., 2009). Finally, we
documented that the cell soma sizes from neurons derived
from the RTT-iPSCs carrying different MeCP2 mutations
were smaller when compared to controls (reduction of 14.31 ±
4.83%). Similarly, loss of function using the shMeCP2 knock-
down strategy in WT neurons reduced soma size at levels
comparable to RTT levels (reduction of 14.52 ± 4.31%) (Figure 4F
and Figure S4D).Rescuing a RTT Neuronal Phenotype
Recent studies have shown that re-activation of MeCP2 expres-
sion knockout mice led to a prolonged life span and delayed
onset or reversal of certain neurological symptoms (Giacometti
et al., 2007; Guy et al., 2007). These reports suggest that some
RTT phenotypes can be rescued in vivo. We used our model to
analyze the effect of selected compounds that may revert the
neuronal phenotype in culture as a validation for future high-
throughput drug screening platforms. Administration of IGF1
was recently described to promote a partial reversal of the
RTT-like symptoms in a mouse model (Tropea et al., 2009). We
treated RTT-derived neurons carrying different MeCP2 muta-
tions in culture with IGF1 and observed an increase in glutama-
tergic synapse number, suggesting that the drug treatment
could correct the RTT neuronal phenotype (Figure 4B and
Figure S4B).
Around 60% of MeCP2 mutations in RTT are nonsense muta-
tions (Laccone et al., 2001). Thus, we tested whether we could
increase MeCP2 expression levels in affected neurons by sup-
pressing the nonsense mutation (Q244X) with read-through of
the premature stop codon using pharmacological treatments.
High concentrations of aminoglycosides antibiotics, such as
gentamicin, can bind to the 16S rRNA, impairing ribosomal
proofreading (Kellermayer, 2006). As a consequence, a full-
length protein is produced by incorporating a random amino
acid at the stop codon position. We treated RTT-Q244X clones
3- and 4-derived neurons with two different doses of gentamicin
and found that MeCP2 protein levels and glutamatergic synapse
numberswere increased after 1week (Figure 4GandFigureS4E).
Treatment with a higher gentamicin dose (400ug/ml) for the same
period did not rescue RTT neurons and lowered the number of
VGLUT1 puncta in control neurons (Figure 4G).
The finding that RTT patient-derived neurons displayed
changes in neuronal morphology and in number of synapses
prompted us to explore putative circuit alterations in vitro.
Altered Activity-Dependent Calcium Transients
in RTT-iPSC-Derived Cells
Early in neural development, spontaneous electrical activity
leads to increases in intracellular calcium levels and activation
of signaling pathways that are important in regulating several
neuronal processes (Spitzer et al., 2004). Recently, a disturbance
in calcium homeostasis during early postnatal development was
reported in a MeCP2 knockout model (Mironov et al., 2009).
Moreover, several studies showed that functional mutations in
genes encoding voltage-gated calcium channels and in genes
whose activity is modulated by calcium, such as MeCP2, could
lead to ASD (Splawski et al., 2006; Zhou et al., 2006). Neuronal
activity-induced calcium influx can trigger the calcium/calmod-
ulin-dependent protein kinase (CamK). CamK activation has
been reported to induce phosphorylation of MeCP2, which
was further postulated to regulate neuronal spine maturation
(Tao et al., 2009; Zhou et al., 2006). Although these studies raised
an interesting link between neuronal activity and spine matura-
tion, the extent of cellular alteration in human ASD neurons
was never characterized. To test if RTT-iPSCs-derived neuronal
networks are affected in our system, we preloaded the cells with
the calcium indicator fluo-4AM and highlighted neurons usingCell 143, 527–539, November 12, 2010 ª2010 Elsevier Inc. 531
Figure 3. RTT-iPSC Clones Undergo X-Inactivation during Differentiation
(A) Schematic representation of X-inactivation dynamics during reprogramming and further neural differentiation. RTT fibroblasts are mosaic for the MeCP2 WT
gene expression. During reprogramming, X-inactivation is erased and iPSCs express both MeCP2 alleles. Upon neuronal differentiation, X-inactivation is re-es-
tablished and the resultant cells are mosaic for MeCP2 WT gene expression.
(B) Immunofluorescence for me3H3K27 in fibroblasts, pluripotent cells (Nanog-positive) and after neuronal differentiation (Syn::EGFP-positive). Pluripotent cells
(hESCs and iPSCs) show diffuse staining whereas differentiated cells (fibroblasts and neurons) exhibit prominent me3H3K27 nuclear foci (arrowheads). Cells
were counterstained with Dapi. The scale bar represents 15 mm.
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the Syn::DsRed vector. Cultures with similar cell density and
numbers of DsRed-positive neurons were used (Figure S2B).
Spontaneous calcium transients were analyzed from WT and
RTT neuronal networks in several independent experiments
over time (Figure 5).
In our analyses, we only considered calcium transients gener-
ated by synaptic activity. Neurons were selected after confirma-
tion that calcium transients were blocked with TTX or with the
glutamate receptor antagonists CNQX (AMPA) and APV
(NMDA) treatments, indicating neuronal signaling dependence
on local synaptic connections (Figures S5A, S5B, and S5D). Ga-
bazine, an antagonist of GABAa receptors, increased the
number of calcium transients in the networks, indicating the
presence of glutamatergic and gabaergic synapses in our
system (Figure S5C, D). A representative example of calcium
tracing in control and RTT neurons is depicted in Figure 5A
and shows a sharp increase in amplitude followed by a decrease
over time. The frequency of calcium oscillations in RTT neurons
and in WT neurons expressing shMeCP2 was abnormally
decreased when compared to controls, suggesting a deficiency
in the neuronal network connectivity and activity dynamics
(Figures 5B and 5C and Figures S5E and S5F). The deficiency
in connectivity was further corroborated by a decrease in the
percentage of Syn::DsRed-positive neurons exhibiting calcium
transients in the RTT cultures when compared to controls (Fig-
ure 5D and Figure S5F).
Decreased Frequency of Spontaneous Postsynaptic
Currents in RTT Neurons
Next we determined the functional maturation of the iPSC-der-
ived neurons using electrophysiological methods. Whole-cell
recordings were performed from cells that had differentiated
for at least 6 weeks in culture. Neurons were visualized by infec-
tion with the Syn::EGFP viral vector (Figure 6A). Both WT and
RTT neurons showed similar transient sodium inward currents,
sustained potassium outward currents in response to voltage
step depolarizations, and action potentials evoked by somatic
current injections (Figure 6B). Therefore, our data indicated
that WT and RTT reprogramming did not affect the ability of
WT-iPSC- and RTT-iPSC-derived neurons to mature and
become electrophysiologically active. We also recorded sponta-
neous excitatory and inhibitory postsynaptic currents (sEPSCs
and sIPSCs) as a way of measuring intercellular connectivity
and network formation (Figures 6B and 6C). Cumulative proba-
bility plots of amplitudes and inter-event intervals of sponta-
neous postsynaptic currents revealed that RTT neurons have
a significant decrease in frequency and amplitude when
compared to WT neurons (Figures 6D and 6E). Together, our
data suggest that the neuronal network is altered in RTT iPSC-
derived cultures.(C) Quantification of cells with diffused or foci me3H3K27 nuclear staining. Data
(D) RNA FISH shows that Xist RNA domains are present in the original fibroblasts
normal and RTT iPSCs show clear Xist clouds, indicating transcriptional silencin
(E) Two DNA FISH signals are evident in the nuclei of iPSC-derived NPCs and neu
10 mm.
(F) RTT-iPSCs (1155del32) expressed WT MeCP2 but derived neurons displayed
scale bar represents 50 mm.
(G) RTT-derived fibroblasts and neurons have reduced levels of WT MeCP2 protDISCUSSION
The lack of detectable symptoms in female RTT patients until
6–18 months of age and the apparent phenotypic reversibility
of some RTT phenotypes in MeCP2 knockout animals indicate
thatMeCP2 is not essential for early wiring of the nervous system
but insteadmay only be required at late stages. It is possible that
RTT patients have aberrant excitatory synaptic strength at very
early stages, when the disease phenotype is not yet clearly
observed. In fact, increasing evidence from clinical studies and
mouse models indicates the presence of alterations during the
so-called presymptomatic developmental phase (Charman
et al., 2002; De Filippis et al., 2009; Kerr et al., 1987; Picker
et al., 2006; Santos et al., 2007).
To study human RTT neurons in culture, we derived iPSCs
from RTT fibroblasts. RTT iPSCs are pluripotent and able to
recapitulate X-inactivation upon neuronal differentiation. Even
though the ratio of neurons expressing mutant MeCP2 due to
X-inactivation was variable, the phenotypes described here for
all RTT-derived neurons are similar. One interpretation could
be that astrocytes, or other nonneuronal cells, carrying MeCP2
mutations present in our cultures could also affect neurons ex-
pressing the normal MeCP2 protein. In fact, the non-cell-auton-
omous influence was recently described for RTT, indicating that
glial cells carrying MeCP2 mutations can distress healthy
neurons (Ballas et al., 2009; Kishi and Macklis, 2010; Maezawa
et al., 2009).
Using human neurons carrying MeCP2 mutations, we showed
that RTT glutamatergic neurons have a reduced number of
synapses and dendritic spines when compared to nonaffected
controls. Moreover, electrophysiological recordings from RTT
neurons showed a significant decrease in the frequency and
amplitude of spontaneous synaptic currents compared to WT
neurons. The reduced frequency in RTT neurons could reflect
the presence of fewer release sites or a decreased release
probability. The results of electrophysiology recordings are
consistent with the decreased VGLUT1 puncta observed in
Map2-positive dendrites from RTT neurons. Also consistent
with these findings, the frequency of intracellular calcium tran-
sients was decreased in RTT neurons when compared to
controls. Our data indicate a potential imbalance in the neuronal
networks associated with RTT pathology. The observations
described here provide valuable information for RTT and, poten-
tially, ASD patients, since they suggest that presymptomatic
defects may represent novel biomarkers to be exploited as diag-
nostic tools and that early intervention may be beneficial.
Therapies aiming at earlier stages of development may atten-
uate the downstream consequences of MeCP2 mutations.
Restoring protein levels may be challenging, since MeCP2 levels
are tightly regulated and chronically overdosing neurons with theshown as mean ± SEM.
before reprogramming. iPSCs show no Xist expression. Neurons derived from
g of the X chromosome (arrows). The scale bar represents 5 mm.
rons, revealing the presence of two X chromosomes. The scale bar represents
mosaicism regarding WT (arrowhead) and mutant (arrow) MeCP2 forms. The
ein by Western blot. See also Figure S3.
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Figure 4. Alterations in RTT Neurons
(A) Proliferating RTT NPCs displayed no signal of aberrant cell cycle when compared to controls.
(B) Representative images of neurons showing VGLUT1 puncta on Map2 neurites. Bar graphs show synaptic density in RTT and WT neurons. IGF1 treatment
increased VGLUT1 puncta number in RTT-derived neurons. The scale bar represents 5 mm.
(C) Reduction of MeCP2 expression decreased the number of glutamatergic synapses in WT neurons.
(D) Overexpression of MeCP2 increased the number of glutamatergic synapses.
(E) Representative images of neurites of different genetic backgrounds. Bar graph shows the spine density from independent experiments using different RTT
backgrounds and controls and after expression of shMeCP2. The scale bar represents 5 mm.
(F) Representative images of neuronal cell body size. Bar graph shows the percentage of soma size decrease in RTT compared to WT neurons. Neuronal
morphology was visualized using the Syn::EGFP lentiviral vector. The scale bar represents 50 mm.
(G) A lower dose of gentamicin was able to rescue glutamatergic synapses in RTT neurons. Numbers of neurons analyzed (n) are shown within the bars in graphs
(E) and (G). For all clones and mutations used refer to Figure S4 and Table S2. Data shown as mean ± SEM.
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Figure 5. Altered Activity-Dependent Calcium Transients in RTT-
Derived Neurons
(A) Representative examples of WT and RTT calcium signal traces. Red traces
correspond to the calcium rise phase detected by the algorithm used (see
Extended Experimental Procedures).
(B) Fluorescence intensity changes reflecting intracellular calcium fluctuations
in RTT and WT neurons in different Regions of Interest (ROI).
(C) RTT neurons show a lower average of calcium spikes when compared to
WT control neurons.
(D) The percentage of Syn::DsRed-positive neurons signaling in the RTT
neuronal network is significantly reduced when compared to controls. Data
shown as mean ± SEM. See also Figure S5.WT allele can be as harmful as a loss of expression (Collins et al.,
2004; Ramocki et al., 2009; Van Esch et al., 2005). Thus, we
tested pharmacological treatment as a way to recover the RTT
neuronal phenotype. We investigated the use of IGF1 in human
neuronal cultures. Although it likely acts in a nonspecific manner,
IGF1 is considered to be a candidate for pharmacological treat-
ment of RTT and potentially other CNS disorders in a future clin-
ical trial (Tropea et al., 2009). While IGF1 treatment increased
synapse number in some clones, it stimulated glutamatergic
RTT neurons above normal levels. Our data indicate that the
IGF1 dose and timing parameters need to be precisely tuned in
future clinical trials to avoid side effects. In a different approach,
we tested a read-through drug (gentamicin) to rescue neurons
derived from iPSCs carrying a nonsense MeCP2 mutation. A
lower dosage of gentamicin was enough to increase full-length
MeCP2 levels in RTT neurons, rescuing glutamatergic synapses.
New drugs with reduced toxicity and enhanced suppression of
premature stop codon mutations might be good therapeutic
candidates (Nudelman et al., 2009; Welch et al., 2007).
Control of glutamatergic synapse number and the other
neuronal phenotypes analyzed here may be caused by loss of
MeCP2 function in the cell. Alternatively, significant experimental
and genomic variability in our system could be directly respon-
sible for the RTT differences displayed in our data. Our gain
and loss of function data strongly suggest that MeCP2 is indeed
the causative agent of the cellular phenotypes reported here that
might be relevant to the clinical features of RTT.
Our data indicate that iPSCs not only can recapitulate some
aspects of a genetic disease but also can be used to better
design and anticipate results from translational medicine. This
cellular model has the potential to lead to the discovery of new
compounds to treat RTT and other forms of ASD. Finally, other
CNS diseases may be modeled in vitro using a similar approach.EXPERIMENTAL PROCEDURES
Cell Culture and Retrovirus Infection
Female RTT and control fibroblasts were generated from explants of dermal
biopsies following informed consent under protocols approved by the Univer-
sity of California San Diego. The Syn::EGFP or DsRed reporter vector was ob-
tained by cloning the Synapsin-1 promoter (a gift from Dr. G. Thiel, Hamburg,
Germany) in a lentivirus backbone. The shRNA against a target sequence on
the humanMeCP2 gene was cloned in the LentiLox3.7 lentivirus vector. Retro-
virus vectors containing the Oct4, c-Myc, Klf4 and Sox2 human cDNAs from
Yamanaka’s group (Takahashi et al., 2007) were obtained from Addgene.
Two days after infection, fibroblasts were plated on mitotically inactivated
mouse embryonic fibroblasts (Chemicon) with hESC medium. After 2 weeks,
iPSC colonies were directly transferred to feeder-free conditions on matrigel-
coated dishes (BD) usingmTeSR1 (StemCell Technologies, and passedmanu-
ally. The detailed protocols to obtain NPCs and mature neurons are described
in the supplemental material. For the rescue experiments, 10 hg/mL of IGF1
(Peprotech) or Gentamicin (Invitrogen; at 100 or 400 mg/mL) was added to
neuronal cultures for 1 week. Protocols were previously approved by the
University of California San Diego and Salk Institute Institutional Review Board
and the Embryonic Stem Cell Research Oversight Committee.
Immunocytochemistry and Neuronal Morphology Quantification
Cells were briefly fixed in 4% paraformaldehyde and then permeabilized with
0.5% Triton X-100 in PBS. Cells were then blocked in PBS containing 0.5%
Triton X-100 and 5% donkey serum for 1 hr before incubation with primary
antibody overnight at 4C. After three washes with PBS, cells were incubatedCell 143, 527–539, November 12, 2010 ª2010 Elsevier Inc. 535
Figure 6. Decreased Frequency of Spontaneous Postsynaptic Currents in RTT Neurons
(A) Fluorescence micrographs of representative WT and RTT neurons. The scale bar represents 10 mm.
(B) Electrophysiological properties of WT and RTT neurons. From top to bottom: Transient Na+ currents and sustained K+ currents in response to voltage step
depolarizations (command voltage varied from20 to +30mV in 5mV increments when cells were voltage-clamped at70mV, Bars = 400 pA and 50ms). Action
potentials evoked by somatic current injections (cells current-clamped at around60mV, injected currents from 10 to 40 pA, Bars = 20mV and 100ms), sEPSCs
(Bars = right, 20 pA, 100 ms; left: 10 pA, 500 ms), and sIPSCs (Bars = right, 20 pA, 500 ms; left: 20 pA, 400 ms).
(C) Sample 4 min recordings of spontaneous currents when the cells were voltage-clamped at 70 mV (Bars = 20 pA and 25 s).
(D) Cumulative probability plot of amplitudes (left panel, 1 pA bins; p < 0.001) and inter-event intervals (right panel, 20ms bins; p < 0.05) of sEPSCs from groups of
WT (black) and RTT (red) cells, respectively.
(E) Cumulative probability plot of amplitudes (left panel, 1 pA bins; p < 0.05) and inter-event intervals (right panel, 20 ms bins; p < 0.05) of sIPSCs from each group
(WT, black; RTT, green).with secondary antibodies (Jackson ImmunoResearch) for 1 hr at room
temperature. Fluorescent signals were detected using a Zeiss inverted micro-
scope and images were processed with Photoshop CS3 (Adobe Systems).
Primary antibodies used in this study are described in the supplemental infor-
mation. Cell soma size was measure in bright field using ImageJ software after
identification of neurons using the Syn::EGFP. The morphologies of neuronal
dendrites and spines were studied from an individual projection of z-stacks
optical sections and scanned at 0.5-mm increments that correlated with the
resolution valued at z-plane. Each optical section was the result of 3 scans
at 500 lps followed by Kalman filtering. For synapse quantification, images
were taken by a z-step of 1 mm using Biorad radiance 2100 confocal micro-
scope. Synapse quantification was done blinded to genotype. Only VGLUT1
puncta alongMap2-positive processes were counted. Statistical significances
were tested using Two-way ANOVA test and Bonferroni post-test.Cell Cycle Analysis
One million NPCs were fixed in 70% EtOH for at least 2 hr at 4C. After PBS
washing, cells were stained with 1 ml of propidium iodide (PI) solution
(50 mg/mL PI in 3.8 Mm sodium citrate) and treated with 20 mL/mL of RNaseA.
Cells were analyzed by fluorescence-activated cell sorting (FACS) on a Becton536 Cell 143, 527–539, November 12, 2010 ª2010 Elsevier Inc.Dickinson LSRI and cell cycle gating was examined using FLOWJO - Flow
Cytometry Analysis Software.
RNA Extraction and RT-PCR
Total cellular RNA was extracted from 5x106 cells using the RNeasy Protect
Mini kit (QIAGEN, Valencia, CA), according to the manufacturer’s instructions,
and reverse transcribed using the SuperScript III First-Strand Synthesis
System RT-PCR from Invitrogen. The cDNA was amplified by PCR using Ac-
cuprime Taq DNA polymerase system (Invitrogen). Primer sequences used
are described in Supplemental information.
Teratoma Formation in Nude Mice
Around 1-3 x106 fibroblasts or iPSCs were injected subcutaneously into the
dorsal flanks of nude mice (CByJ.Cg-Foxn1nu/J) anesthetized with isoflurane.
Five to six weeks after injection, teratomas were dissected, fixed overnight in
10% buffered formalin phosphate and embedded in paraffin. Sections were
stained with hematoxylin and eosin for further analysis. Control mice injected
with RTT fibroblasts failed to form teratomas. Protocols were previously
approved by the University of California San Diego Institutional Animal Care
and Use Committee.
Karyotyping and DNA Fingerprinting
Standard G-banding chromosome and DNA fingerprinting analysis was per-
formed by Cell Line Genetics (Madison, WI).
DNA and RNA FISH
Xist RNA exon 6 probes (GenBank U80460: 75081-78658 – a gift from
Dr. Jeannie T. Lee, Massachusetts General Hospital, Harvard Medical School)
were transcribed by using T7 RNA polymerase (Roche) with AlexaFluor 488-5-
UTP. X chromosome probe and Xist slide hybridization were performed by
Molecular Diagnostic Services, Inc. (San Diego, CA).
Protein Isolation and Western Blot Analysis
Cells were isolated, suspended in 13 RIPA lyses buffer (Upstate) supple-
mented with 1% protease inhibitor cocktail (Sigma), triturated and centrifuged
at 10,0003 g for 10 min at 4C. Twenty micrograms of total protein was sepa-
rated on 12% SDS-polyacrylamide gel, transferred to a nitrocellulose
membrane and probed with a primary antibody against MeCP2 (1:5,000; Dia-
genode), followed by horseradish-peroxidase-conjugated secondary antibody
(1:5,000; Promega), and then visualized using ECL chemiluminescence (Amer-
sham). As a control, membranes were stripped and re-probed for b-actin
(1:10,000; Ambion) or a–tubulin (1:5,000, Ambion). For semiquantitative anal-
ysis, MeCP2 signal intensity was analyzed and corrected with respect to
b-actin.
Microarray Analysis
The Affymetrix Power Tools (APT) suite of programs and Affymetrix Human
Gene 1.0 ST Arrays library files and annotation were obtained from http://
www.affymetrix.com/support and details of the analysis are available in
Supplemental information.
Calcium Imaging
Neuronal networks derived from human iPSCs were previously infected with
the lentiviral vector carrying the Syn:DsRed reporter construct. Cell cultures
were washed twice with sterile Krebs HEPES Buffer (KHB) and incubated
with 2–5 mM Fluo-4AM (Molecular Probes/Invitrogen, Carlsbad, CA) in KHB
for 40 min at room temperature. Excess dye was removed by washing twice
with KHB and an additional 20 min incubation was done to equilibrate intracel-
lular dye concentration and allow de-esterification. Time-lapse image
sequences (1003 magnification) of 5000 frames were acquired at 28 Hz with
a region of 336 3 256 pixels, using a Hamamatsu ORCA-ER digital camera
(Hamamatsu Photonics K.K., Japan) with a 488 nm (FITC) filter on an Olympus
IX81 inverted fluorescence confocal microscope (Olympus Optical, Japan).
Images were acquired with MetaMorph 7.7 (MDS Analytical Technologies,
Sunnyvale, CA). Images were subsequently processed using ImageJ (http://
rsbweb.nih.gov/ij/) and custom written routines in Matlab 7.2 (Mathworks, Na-
tick, MA). Detailed quantitative analysis of calcium transients is available in the
Supplemental material.
Electrophysiology
Whole-cell patch clamp recordingswere performed fromcells co-culturedwith
astrocytes after 6 weeks of differentiation. The bath was constantly perfused
with fresh HEPES-buffered saline (see supplemental methods for recipe). The
recordingmicropipettes (tip resistance3–6MU) were filledwith internal solution
described in the Supplemental materials. Recordings were made using
Axopatch 200B amplifier (Axon Instruments). Signals were filtered at 2 kHz
and sampled at 5 kHz. The whole-cell capacitance was fully compensated.
The series resistance was uncompensated but monitored during the experi-
ment by the amplitude of the capacitive current in response to a 10 mV pulse.
All recordings were performed at room temperature and chemicals were
purchased from Sigma. Frequency and amplitude of spontaneous postsyn-
aptic currentsweremeasuredwith theMini Analysis Program software (Synap-
tosoft, Leonia, NJ). Statistical comparisons of WT and RTT groups were made
using the nonparametric Kolmogorov-Smirnov two-tailed test, with a signifi-
cance criterion of p = 0.05. EPSCs were blocked by CNQX or DNQX
(10–20 mM) and IPSPs were inhibited by bicuculine (20 mM).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and two tables and can be found with this article online at doi:10.
1016/j.cell.2010.10.016.
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